Laboratory & Diagnostics

SHERIDAN, WYOMING – May 8, 2025 – Roche has achieved a significant milestone in oncology diagnostics with the U.S. Food and Drug Administration (FDA) granting Breakthrough Device Designation for its VENTANA® TROP2 (EPR20043) RxDx Device. This marks the first FDA recognition for a computational pathology companion diagnostic (CDx) device using artificial intelligence, highlighting Roche's continued leadership in cancer diagnostics and precision medicine.

The innovative VENTANA TROP2 RxDx device leverages AI to enhance diagnostic precision, improving the detection of non-small cell lung cancer (NSCLC) and enabling personalized treatment decisions. By utilizing cutting-edge digital pathology and AI-driven algorithms, Roche is setting a new standard for oncological diagnostics, advancing both the accuracy and speed of patient treatment strategies.

SHERIDAN, WYOMING – May 8, 2025 – Thermo Fisher Scientific Inc. (NYSE: TMO), a global leader in serving science, has announced that Marc N. Casper, the company’s chairman, president, and chief executive officer, will be presenting at the highly anticipated BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 11:40 a.m. (ET). The presentation will be available via a live webcast, accessible through the Investors section of Thermo Fisher’s official website.

SHERIDAN, WYOMING – May 08, 2025 – Agilent Technologies Inc. (NYSE: A) has introduced its highly anticipated Seahorse XF Flex Analyzer, an advanced, high-performance 24-well system designed to propel metabolic analysis in complex 3D tissue and organoid models. This groundbreaking tool, accompanied by dedicated consumables and kits, promises to transform the way researchers study cellular metabolism, providing critical insights into disease mechanisms and therapeutic development.

Enhancing Metabolic Research Capabilities

Metabolism plays a central role in cellular functions, powering energy production and processes like biosynthesis, mitochondrial function, and cell fate decisions. Disruptions in metabolism are linked to numerous diseases, making metabolic analysis a critical area of research. Traditionally, 2D models have been used for this purpose, but they often fail to reflect the complex biological interactions that occur in living organisms.

SHERIDAN, WYOMING – May 8, 2025 – Agilent Technologies Inc. (NYSE: A) is set to highlight its groundbreaking solutions and strategic collaborations at the upcoming American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois, from April 25-30, 2025. Agilent’s innovative products, including advanced DNA cancer panels, multiomic profiling assays, and cutting-edge companion diagnostics, will take center stage, reflecting the company’s commitment to advancing cancer research and therapeutic development.

SHERIDAN, WYOMING – May 8, 2025 – Agilent Technologies Inc. (NYSE: A) has announced that its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has achieved European IVDR certification. This certification positions the assay as a Companion Diagnostic (CDx) to identify gastric or gastroesophageal junction (GEJ) adenocarcinoma patients eligible for treatment with KEYTRUDA® (pembrolizumab), a leading anti-PD-1 therapy developed by Merck. The certification expands the test’s application, offering a significant advancement in cancer treatment options for a growing patient demographic.

SHERIDAN, WYOMING – May 8, 2025 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, has announced its financial results for the first quarter of 2025. Despite navigating a challenging macroeconomic landscape, the company demonstrated solid operational performance, underscoring its commitment to driving growth and margin expansion amidst market volatility.

Financial Performance Overview

For the first quarter of 2025, Bio-Rad reported total net sales of $585.4 million, reflecting a 4.2% decrease from the $610.8 million recorded in Q1 2024. On a currency-neutral basis, the decrease was moderated to 1.5%. This decline was primarily attributed to softer sales in the Life Science segment, compounded by a decrease in academic research funding, particularly in the Americas.

Key Financial Highlights:

SHERIDAN, WYOMING – May 8, 2025 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a recognized leader in life science research and clinical diagnostics products, is set to announce its first-quarter financial results for 2025 on Thursday, May 1, 2025. The company will release its earnings after market close, followed by a detailed conference call to discuss the results.

Key Highlights of the Upcoming Report

Bio-Rad, headquartered in Hercules, California, is poised to share insights into its financial performance, reflecting ongoing growth and market leadership in the life sciences sector. The company’s diverse product portfolio spans across research and clinical diagnostics, with an emphasis on innovation and customer success.

SHERIDAN, WYOMING – May 7, 2025 – Hologic, Inc. (Nasdaq: HOLX), a leader in medical technologies focused on women’s health, today announced its financial results for the second quarter of fiscal 2025. The company reported revenue of $1,005.3 million, slightly surpassing the upper end of its guidance, despite a decline in overall earnings per share (EPS) due to non-cash impairment charges. Hologic’s performance was primarily driven by strong demand in its diagnostics and skeletal businesses, along with ongoing profitability improvements and strategic share buybacks.

SHERIDAN, WYOMING – May 6, 2025 – BD (Becton, Dickinson and Company), a global leader in medical technology, has announced the induction of Eric Diebold, Ph.D., Vice President and General Manager of Instruments, Software, and Informatics, Biosciences, to the prestigious American Institute for Medical and Biological Engineering (AIMBE) College of Fellows. This distinction, awarded to individuals who have made pioneering contributions to the field, underscores the significant role that Diebold has played in advancing medical and biological engineering, particularly in the realms of photonics, high-speed imaging, and flow cytometry.

SHERIDAN, WYOMING – May 6, 2025 – BD (Becton, Dickinson and Company), a global leader in medical technology, has announced its participation in the upcoming Bank of America Securities Health Care Conference, scheduled for Tuesday, May 13, 2025, at 1:00 pm Eastern Time. The live webcast of the presentation will be available on the BD investor relations website, with a replay accessible afterward for those unable to attend the live event.

BD’s Commitment to Innovation in Health Care

BD continues to lead the charge in transforming the medical technology landscape. With a vast portfolio of cutting-edge solutions, BD plays a critical role in advancing medical discovery, diagnostics, and the delivery of care. Through its presentation at the prestigious Bank of America Securities Health Care Conference, BD aims to further demonstrate how its innovations enhance the safety, efficiency, and quality of care for both patients and healthcare providers.